Prime Editing: A Revolutionary Technology for Precise Treatment of Genetic Disorders
Cell Proliferation · 2025-04 · 58 (4)
DOI: 10.1111/cpr.13808 ↗At a glance
Übersichtsarbeit in Cell Proliferation, published online on 2025-02-27. Written by Mengyao Li and 3 co-authors. Institution: State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China. Major MEDLINE topics: Gene Editing, Genetic Diseases, Inborn, Genetic Therapy. Cited 26 times so far (Crossref); 179 references. The full text is freely available (open access, CC BY 4.0). Funded by: Noncommunicable Chronic Diseases-National Science and Technology Major Project, Initiative Scientific Research Program, Institute of Zoology, Chinese Academy of Sciences, Beijing-Tianjin-Hebei Basic Research Cooperation Project.
Abstract (original language)
Genetic diseases have long posed significant challenges, with limited breakthroughs in treatment. Recent advances in gene editing technologies offer new possibilities in gene therapy for the treatment of inherited disorders. However, traditional gene editing methods have limitations that hinder their potential for clinical use, such as limited editing capabilities and the production of unintended byproducts. To overcome these limitations, prime editing (PE) has been developed as a powerful tool for precise and efficient genome modification. In this review, we provide an overview of the latest advancements in PE and its potential applications in the treatment of inherited disorders. Furthermore, we examine the current delivery vehicles employed for delivering PE systems in vitro and in vivo, and analyze their respective benefits and limitations. Ultimately, we discuss the challenges that need to be addressed to fully unlock the potential of PE for the remission or cure of genetic diseases.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
- Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
- Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.
- University of Chinese Academy of Sciences, Beijing, China.
- Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing, China.
- Beijing Advanced Center of RNA Biology, Peking University, Beijing, China.
ORCID profiles: Mengyao Li, Yi Lin, Qiang Cheng, Tuo Wei
Funding
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- Initiative Scientific Research Program, Institute of Zoology, Chinese Academy of Sciences
- Beijing-Tianjin-Hebei Basic Research Cooperation Project
- the "Open Competition to Select the Best Candidates" Key Technology Program for Nucleic Acid Drugs of NCTIB
- the Fundamental Research Funds for the Central Universities, Peking University
- the Beijing Life Science Academy
- China Postdoctoral Science Foundation
Cite
APA
Li, M., Lin, Y., Cheng, Q., & Wei, T. (2025). Prime Editing: A Revolutionary Technology for Precise Treatment of Genetic Disorders. Cell Proliferation, 58(4). https://doi.org/10.1111/cpr.13808
Vancouver
Li M, Lin Y, Cheng Q, Wei T. Prime Editing: A Revolutionary Technology for Precise Treatment of Genetic Disorders. Cell Proliferation. 2025;58(4). doi:10.1111/cpr.13808
BibTeX
@article{Li2025,
author = {Li, Mengyao and Lin, Yi and Cheng, Qiang and Wei, Tuo},
title = {Prime Editing: A Revolutionary Technology for Precise Treatment of Genetic Disorders},
journal = {Cell Proliferation},
year = {2025},
volume = {58},
number = {4},
doi = {10.1111/cpr.13808}
}
EUVIMED